Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia

BMC Veterinary Research

Research Article

Cheryl A. London¹  Christian Schoen²  Roberta Portela³  Heather L. Gardner⁴  Elizabeth M. Schuh⁵ 

[1] College of Veterinary Medicine, The Ohio State University, Columbus OH AND Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA;Nanopartz Inc., 146 Barberry Place, 80537, Loveland, CO, USA;Premier Veterinary Group, 3927 W. Belmont Ave, 60618, Chicago, IL, USA;Sackler School at Tufts University, Boston, MA, USA;Veterinary Cancer Group, 2887 Edinger Ave, 92780, Tustin, CA, USA;

关键词: Hyperthermia;    Plasmonic photothermal therapy;    Gold nanorod;    Dog;    Tumor;   

DOI  :  10.1186/s12917-017-1209-y

 received in 2016-07-27, accepted in 2017-09-14,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundHyperthermia is an established anti-cancer treatment but is limited by tolerance of adjacent normal tissues. Parenteral administration of gold nanorods (NRs) as a photosensitizer amplifies the effects of hyperthermia treatment while sparing normal tissues. This therapy is well tolerated and has demonstrated anti-tumor effects in mouse models. The purpose of this phase 1 study was to establish the safety and observe the anti-tumor impact of gold NR enhanced (plasmonic) photothermal therapy (PPTT) in client owned canine patients diagnosed with spontaneous neoplasia.ResultsSeven dogs underwent gold NR administration and subsequent NIR PPTT. Side effects were mild and limited to local reactions to NIR laser. All of the dogs enrolled in the study experienced stable disease, partial remission or complete remission. The overall response rate (ORR) was 28.6% with partial or complete remission of tumors at study end.ConclusionsPPTT utilizing gold nanorod therapy can be safely administered to canine patients. Further studies are needed to determine the true efficacy in a larger population of canine cancer patients and to and identify those patients most likely to benefit from this therapy.

【 授权许可】

CC BY   
© The Author(s). 2017